Super proteins including interferons, interleukins, et al.
OwnerSidney Pestkainventor
Life of this patent
Estimating the term…
Abstract
A new class of polypeptides is disclosed, along with a method for identifying and producing such polypeptides, having the characteristic of being unique to diseased states, particularly tumors and blood-borne malignancies. These new polypeptides are active and will be useful for therapeutic purposes.
Claims36
A method of identifying and producing modified polypeptides comprising the steps of:
- selecting diseased cells from which specific nucleotide sequences may be obtained;
- determining an appropriate primer pair to encompass at least a portion of a nucleotide sequence to amplify said nucleotide sequence;
- screening cloned nucleotide sequences obtained from said diseased cells for modified sequences to identify sequences that encode said modified polypeptides,
- expressing said modified polypeptides, and
- comparing said modified polypeptides with amino acid sequences for proteins obtained from non-diseased cells to determine polypeptides having characteristics different from said non-diseased proteins.
The method of claim I wherein said selected diseased cells are derived from leukemic leukocytes.
A recombinantly produced polypeptide having interferon activity, being derived uniquely from diseased cells and being a modification of the natural IFN α species.
A recombinantly produced polypeptide having interferon activity, being derived uniquely from diseased cells and being a modification of the natural IFN β species.
A recombinantly produced polypeptide having interferon activity, being derived uniquely from diseased cells and being a modification of the natural IFN γ species.
A recombinantly produced polypeptide having interleukin-2 activity, being derived uniquely from diseased cells and being a modification of the natural interleukin-2 species.
Human leukocyte interferon wherein the interferon has the amino acid sequence from position 1 to position 166 as depicted for hu-IFN-α001 in FIG. 1.
A recombinantly produced polypeptide having interferon activity and comprising the amino acid sequence of Hu-IFN-α001.
- 6 CysAspLeuProGlnThrHisSerLeuArgAsnArgArgAlaLeuIleLeuLeuAlaGln 1 10 20 MetGlyArgIleSerProPheSerCysLeuLysAspArgHisGluPheArgPheProGlu 30 40 GluGluPheAspGlyHisGlnPheGlnLysThrGlnAlaIleSerValLeuHisGluMet 50 60 IleGlnGlnThrPheAsnLeuPheSerThrGluAspSerSerAlaAlaTrpGluGlnSer 70 80 LeuLeuGluLysPheSerThrGluLeuTyrGlnGlnLeuAsnAspLeuGluAlaCysVal 90 100 IleGlnGluValGlyValGluGluThrProLeuMetAsnGluAspSerIleLeuAlaVal 110 120 ArgLysTyrPheGlnArgIleThrLeuTyrLeuThrGluLysLysTyrSerProCysAla 130 140 TrpGluValValArgAlaGluIleMetArgSerLeuSerPheSerThrAsnLeuGlnLys 150 160 ArgLeuArgArgLysAspEnd 166
A DNA sequence comprising a sequence coding for the polypeptide comprising the amino acid sequence of human IFN-α001.
A replicable expression vector capable of expressing a polypeptide comprising the amino acid sequence of human IFN-α001 as a mature human leukocyte interferon.
Plasmid pHu-IFN-α001 deposited with the American Type Culture Collection under Accession Number:______
Dependencies are inferred from the claim text.